Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A. Yardley; Jose Bines; Richard D. Gelber; Martine Piccart; APHINITY Steering Comm; Vivianne Tjan - Heijnen; Jose Baselga

doi:10.1056/NEJMoa1703643

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Adam Knott, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine Piccart, APHINITY Steering Comm, Vivianne Tjan - Heijnen, Jose Baselga

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	122-131
Number of pages	10
Journal	New England Journal of Medicine
Volume	377
Issue number	2
DOIs	https://doi.org/10.1056/NEJMoa1703643
Publication status	Published - 13 Jul 2017

Keywords

PLUS DOCETAXEL
CHEMOTHERAPY
EFFICACY

Access to Document

10.1056/NEJMoa1703643

Cite this

von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M., APHINITY Steering Comm, Tjan - Heijnen, V., & Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 377(2), 122-131. https://doi.org/10.1056/NEJMoa1703643

von Minckwitz, Gunter ; Procter, Marion ; de Azambuja, Evandro ; Zardavas, Dimitrios ; Benyunes, Mark ; Viale, Giuseppe ; Suter, Thomas ; Arahmani, Amal ; Rouchet, Nathalie ; Clark, Emma ; Knott, Adam ; Lang, Istvan ; Levy, Christelle ; Yardley, Denise A. ; Bines, Jose ; Gelber, Richard D. ; Piccart, Martine ; APHINITY Steering Comm ; Tjan - Heijnen, Vivianne ; Baselga, Jose. / Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. In: New England Journal of Medicine. 2017 ; Vol. 377, No. 2. pp. 122-131.

@article{d26f27d7a201464b87ed6357d591f20b,

title = "Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer",

keywords = "PLUS DOCETAXEL, CHEMOTHERAPY, EFFICACY",

author = "{von Minckwitz}, Gunter and Marion Procter and {de Azambuja}, Evandro and Dimitrios Zardavas and Mark Benyunes and Giuseppe Viale and Thomas Suter and Amal Arahmani and Nathalie Rouchet and Emma Clark and Adam Knott and Istvan Lang and Christelle Levy and Yardley, {Denise A.} and Jose Bines and Gelber, {Richard D.} and Martine Piccart and {APHINITY Steering Comm} and {Tjan - Heijnen}, Vivianne and Jose Baselga",

year = "2017",

month = jul,

day = "13",

doi = "10.1056/NEJMoa1703643",

language = "English",

volume = "377",

pages = "122--131",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOCIETY",

number = "2",

}

von Minckwitz, G, Procter, M, de Azambuja, E, Zardavas, D, Benyunes, M, Viale, G, Suter, T, Arahmani, A, Rouchet, N, Clark, E, Knott, A, Lang, I, Levy, C, Yardley, DA, Bines, J, Gelber, RD, Piccart, M, APHINITY Steering Comm, Tjan - Heijnen, V & Baselga, J 2017, 'Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer', New England Journal of Medicine, vol. 377, no. 2, pp. 122-131. https://doi.org/10.1056/NEJMoa1703643

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. / von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Lang, Istvan; Levy, Christelle; Yardley, Denise A.; Bines, Jose; Gelber, Richard D.; Piccart, Martine; APHINITY Steering Comm ; Tjan - Heijnen, Vivianne; Baselga, Jose.

In: New England Journal of Medicine, Vol. 377, No. 2, 13.07.2017, p. 122-131.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

AU - von Minckwitz, Gunter

AU - Procter, Marion

AU - de Azambuja, Evandro

AU - Zardavas, Dimitrios

AU - Benyunes, Mark

AU - Viale, Giuseppe

AU - Suter, Thomas

AU - Arahmani, Amal

AU - Rouchet, Nathalie

AU - Clark, Emma

AU - Knott, Adam

AU - Lang, Istvan

AU - Levy, Christelle

AU - Yardley, Denise A.

AU - Bines, Jose

AU - Gelber, Richard D.

AU - Piccart, Martine

AU - APHINITY Steering Comm

AU - Tjan - Heijnen, Vivianne

AU - Baselga, Jose

PY - 2017/7/13

Y1 - 2017/7/13

KW - PLUS DOCETAXEL

KW - CHEMOTHERAPY

KW - EFFICACY

U2 - 10.1056/NEJMoa1703643

DO - 10.1056/NEJMoa1703643

M3 - Article

VL - 377

SP - 122

EP - 131

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -